APLS

Apellis Pharmaceuticals, Inc.

40.04 USD
+1.62 (+4.22%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Apellis Pharmaceuticals, Inc. stock is down -1.28% since 30 days ago. The next earnings date is Jul 29, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 85.71% of the previous 6 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
12 Jun 19:56 21 Jun, 2024 40.00 PUT 375 2176
18 Jun 14:05 21 Jun, 2024 55.00 PUT 37 394
20 Jun 14:44 18 Oct, 2024 40.00 CALL 150 32
21 Jun 13:39 21 Jun, 2024 40.00 PUT 750 2222
21 Jun 17:08 21 Jun, 2024 90.00 PUT 5 1079
21 Jun 19:18 17 Jan, 2025 65.00 PUT 10 184
21 Jun 19:41 16 Jan, 2026 45.00 PUT 80 423
21 Jun 19:58 16 Aug, 2024 40.00 CALL 300 338
24 Jun 14:09 17 Jan, 2025 75.00 PUT 31 25
24 Jun 15:00 19 Jul, 2024 40.00 PUT 98 294

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

  • Piper Sandler
    Fri May 31, 05:54
    hold
    initial
  • HC Wainwright & Co.
    Tue May 28, 06:29
    buy
    confirm